Alkem Laboratories

Stocks to Watch today, June 3: Infosys, Alkem Labs, Paytm among others in focus; here's why

The company has received DCGI approval for multiple dosage strengths and aims to widen access to semaglutide treatment for diabetes and obesity

In the March quarter, Alkem Laboratories reported a fall in consolidated net profit by 22.7 per cent year-on-year (Y-o-Y) for the fourth quarter (Q4) of the financial year 2025-26 (FY26) to ₹236 crore

Stocks to Watch today, May 29, 2026: Ashok Leyland, Alkem Laboratories, PhysicsWallah, GMR Airports, InterGlobe Aviation, NMDC, and Glenmark Pharma are among the top stocks to remain in focus today

The drugmaker said strong domestic branded generics and international business growth helped drive record EBITDA performance in FY26

Q4FY26 company results: Firms including Bharat Dynamics, Schneider Electric Infra, Deepak Fertilisers & Petrochemicals, and Apar Industries are also to release their January-March earnings today

Alkem Laboratories Ltd on Thursday announced almost doubling of investment to up to Rs 1,036 crore for its proposed greenfield formulations manufacturing facility in Ujjain, Madhya Pradesh. The board of the directors of the company on April 2 has approved an increase in investment from up to Rs 533 crore to up to Rs 1,036 crore to be made in a phased manner for setting up of manufacturing facility in Ujjain, Alkem Laboratories Ltd said in a regulatory filing. Earlier on March 18, the company had stated that it has received allotment letter from DMIC Vikram Udyogpuri Ltd, for allotment of 30 acres land for setting up of the greenfield formulations manufacturing facility at Ujjain and the company's board had approved an investment of up to Rs 533 crore to be made in a phased manner.

Here is the complete list of the stocks trading ex-dividend tomorrow, along with their respective record dates and announced dividend amounts

Nomura has maintained its Nifty target for March 2026 at 26,140, implying a modest upside of 4 per cent from current levels, based on a FY27F earnings per share (EPS) estimate of ₹1,245.

Stocks to Watch today, September 29, 2025: From Tata Motors, Oil India to Shriram Finance, here is a list of stocks that will be in focus

Stocks to Watch today, September 23, 2025: JBM Auto, Vedanta, JK Lakshmi, Dr Reddy's Labs and other stocks will be in focus

Alkem Laboratories on Monday said it has launched a biosimilar product in India for the treatment of breast cancer. The company has introduced Pertuza injection 420mg/14mL, a pertuzumab biosimilar, for the treatment of HER2-positive breast cancer, the drug firm said in a statement. Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab, it added. "Oncology is a priority area for Alkem, and our efforts are focused on developing treatment options that combine scientific excellence with wider access. The launch of Pertuza reflects this commitment and further strengthens our oncology portfolio," Alkem CEO Vikas Gupta said. Shares of the company on Monday ended 0.69 per cent down at Rs 5,496 apiece on BSE.

Alkem Labs Q1FY26 profit rose 22% YoY to ₹664.3 crore, with strong growth in India and international sales; company to boost focus on high-potential non-US markets

IPO-bound Allchem Lifesciences adds legal dispute with Alkem to DRHP as Delhi HC directs both firms to mediation and next hearing is scheduled for 9 July

Next resistance for the Nifty50 is seen at 24,545, which happens to be 61.8 per cent retracement of the entire fall seen from 26,277 to 21,743

Semaglutide, an active ingredient in drugs like Ozempic and Wegovy, is owned and produced by Novo Nordisk and is set to go off-patent in India in March 2026

The company's revenue from operations increased to Rs 3,374 crore in Q3 FY25, a marginal 1.5 per cent Y-o-Y rise from Rs 3,324 crore in Q3 FY24

The company along with its arm will acquire a 26 per cent stake in the Capital of Sunsure Solarpark

Technical charts indicate that the 5 newly added stocks to the MSCI index are favourably placed and could soar up to 19% in forthcoming trading sessions.

Company claims samples of Pan-D, Clavam 625 tested were spurious, not manufactured by it